Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esketamine Nasal Spray Monotherapy in Treatment-resistant Depression (Japan)
jRCT2031260211Not yet recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of esketamine in major depressive disorder (MDD) (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Change From Baseline in MADRS Total Score. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
esketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on jRCT2031260211.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260211.